Scilex Holding Company

NASDAQ:SCLX

Drug Manufacturers - General

Healthcare
$6.34 -2.38%

-$0.17 today

Market cap
$53.83M
Beta
1.71
P/E (TTM)
-0.1
EPS (TTM)
-$60.90
52W Low $2.62High $21.34

Volume 0.00M

Average 0.13M

SCLX Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Scilex Holding CompanyNASDAQ: SCLX

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables growth accelerates

Q1 FY2026 accounts payables of $15.81M rose 208.3% year over year, ahead of the +109.8% change in trailing-twelve-month accounts payables. Sequentially, it rose 864.1% from the prior quarter. Over 3 fiscal years it compounded at +67.2% a year.

Context

  • Accounts payables amounted to 43.4% of revenue in FY2025, up 30.3 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +208.3% holds above the trailing-twelve-month pace of +109.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.81M+864.1% QoQ
Last fiscal yearDec 2025
$13.12M+76.9% YoY
LTMMar 2026
$23.68M+109.8% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+208.3%——
1 year+76.9%——
3-year CAGR+67.2%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
13.12M USD
Year-over-year change
+76.9%

Accounts Payables vs competitors

How SCLX compares with its peers on the latest reported figures

  • SCLX's LTM Mar 2026 accounts payables of $23.68M is the largest of the 9 companies compared; the peer median is $397.5K.
  • Its year-over-year change of +109.8% is the 4th highest of 9, against a peer median of -23.7%.
  • Accounts payables amounts to 69.9% of revenue for SCLX, versus a peer median of 10.0%.
SCLX Competitors Peer median
Accounts Payables for SCLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SCLXScilex Holding CompanyLTM Mar 2026$23.68M +109.8%+67.2%69.9%
AGENAgenus Inc.LTM Mar 2026$8.98M -41.7%+53.5%7.2%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$4.12M -5.6%——
SEERSeer, Inc.LTM Mar 2026$1.93M -198.4%—12.8%
IRDOpus Genetics, Inc.LTM Mar 2026$1.88M +559.7%—15.7%
CTORCitius Oncology, Inc.LTM Mar 2026$1.25M -80.3%—22.3%
ALECAlector, Inc.LTM Mar 2026$903K -59.8%-2.9%4.9%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$545K +126.9%——
LUCDLucid Diagnostics Inc.LTM Mar 2026$250K +278.6%-15.3%4.9%
Peer median (excluding SCLX) $397.5K-23.7%-2.9%10.0%

Competitors are the stored peer set for SCLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(88.42M)(23.36M)(114.33M)(72.81M)(358.73M)
Depreciation & Amortization3.78M3.96M4.15M4.05M4.62M
Deferred Income Tax12.76M0000
Stock-Based Compensation5.82M5.28M14.6M15.69M15.49M
Change in Working Capital13.6M45.67M65.8M64.84M113.97M
Accounts Receivables(1.14M)(6.97M)(13.36M)(6.27M)13.84M
Inventory(1.42M)1.18M(2.84M)1.46M1.8M
Accounts Payables(3.84M)2.81M19.88M7.42M13.12M
Other Working Capital20M48.65M62.12M62.23M85.21M
Other Non-Cash Items23.79M(52.8M)9.08M7.58M228.47M
Operating Cash Flow(28.66M)(21.26M)(20.71M)19.35M3.82M
Capital Expenditures0(2.07M)(330K)(600K)(133K)
Acquisitions (Net)00000
Purchases of Investments000(2.08M)0
Sales of Investments00000
Other Investing Activities00(300K)04.22M
Investing Cash Flow0(2.07M)(330K)(2.68M)4.08M
Debt Repayment(19.69M)(31.25M)728K(64.21M)(2.81M)
Common Stock Issued096K35.46M44.64M27.88M
Common Stock Repurchased00(10M)00
Dividends Paid00000
Other Financing Activities47.85M52.33M(2.6M)1.44M(30.53M)
Financing Cash Flow28.16M21.17M23.58M(18.13M)(5.46M)
Effect of Forex Changes0000(756K)
Net Change in Cash(501K)(2.15M)2.55M(1.46M)1.68M
Free Cash Flow(28.66M)(23.33M)(21.04M)18.75M3.68M

Scilex Holding Company

NASDAQ:SCLX

Intrinsic Alpha fair value

Locked

Current Price

$6.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.